Research News and Research

RSS

Autism-vaccine link study – Complete fraud

There has been a controversy regarding the causative link of vaccines with autism. A report appeared in the British Medical Journal this Wednesday that stated that Dr. Andrew Wakefield, the lead author of a major study to imply such a link had falsified the medical histories of all 12 patients in his study and that he was “hoping to sue vaccine manufacturers and to create a vaccine scare.”

9 Jan 2011

Malaria drug makes cancer drug more effective

Scientists investigating the cancer-fighting properties of artesunate - a drug commonly used to treat malaria - have found early evidence that combining it with an existing cancer drug has the potential to make each drug more effective than when used alone. They also found that regular treatment breaks could improve success levels.

7 Jan 2011

Infinity provides guidance on anticipated pipeline and business goals for 2011

Infinity Pharmaceuticals, Inc. today provided guidance on its anticipated pipeline and business goals for 2011. Infinity begins the year with a broad pipeline of four drug candidates in clinical development and a fifth expected to enter the clinic during the year. The company also enters 2011 with approximately $345 million in committed capital.

7 Jan 2011

MedImmune announces in-licensing agreement with Amgen for IL-1 pathway targeting novel monoclonal antibody

MedImmune today announced an in-licensing agreement with Amgen for a novel monoclonal antibody targeting the IL-1 pathway. The antibody, AMG 108, a fully human monoclonal antibody to the IL-1 receptor, has been studied in multiple phase 1 and phase 2 clinical trials and will now be explored by MedImmune for its potential against certain inflammatory diseases.

7 Jan 2011

Scientists identify type of cell at the origin of brain tumors

Scientists have identified the type of cell that is at the origin of brain tumors known as oligodendrogliomas, which are a type of glioma - a category that defines the most common type of malignant brain tumor.

7 Jan 2011

Iroko reports positive results from Phase I clinical study of nanotechnology based unique formulation of naproxen

Iroko Pharmaceuticals, LLC today reported the results of the Phase I clinical study of its unique formulation of naproxen, a widely used pain medication, using proprietary, patent protected nanotechnology.

7 Jan 2011

Majority of U.S. adults strongly support innovative programs to discourage teen pregnancy

Every hour in the United States, about 40 children are born to teenage mothers. Americans consistently rate teen pregnancy as one of the top 10 biggest health problems for young people and the U.S. still has the highest teen birth rate among all industrialized countries -- despite decreases in the birth rate during the past 20 years.

7 Jan 2011

Unexpected discovery holds promise for PTSD, other anxiety disorders

An unexpected discovery by UCLA life scientists holds promise for the future development of treatments for post-traumatic stress disorder and other anxiety disorders, and potentially for Alzheimer's disease and other memory-impairment diseases.

7 Jan 2011

Sutro, Pfizer enter multi-year collaboration for novel peptide-based therapeutics

Sutro Biopharma, a biopharmaceutical company developing novel and biosuperior protein therapeutics with improved pharmaceutical properties, today announced that the company has entered into a multi-year collaboration with Pfizer for the research, development and commercialization of novel peptide-based therapeutics.

7 Jan 2011

Radiosurgery may bring improvement for patients with extremely severe -compulsive disorder

For patients with extremely severe -compulsive disorder (OCD), a procedure called radiosurgery may bring improvement when other treatments have failed, according to a study in the January issue of Neurosurgery, official journal of the Congress of Neurological Surgeons. The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health.

7 Jan 2011

Aratana closes $20 million Series A financing

Aratana Therapeutics, a newly-formed company focused on the development of innovative therapies for the animal health industry, today announced that it has closed a $20 million Series A financing led by MPM Capital and Avalon Ventures.

7 Jan 2011

Critical Diagnostics' high sensitivity Presage ST2 Assay receives CE Mark approval

Critical Diagnostics announced today that it has received CE (Conformité Européenne) Mark for its high sensitivity Presage ST2 Assay and is commencing commercialization in Europe. The product is indicated for use as an aid in risk stratification of patients with heart failure or acute coronary syndrome. This regulatory milestone marks the first time that an assay has become commercially available for the clinical measurement of the biomarker soluble ST2.

7 Jan 2011

MMRF awards $3 million under 2010 Biotech Investment Awards program

The Multiple Myeloma Research Foundation (MMRF) today announced that it has awarded $1 million to each of three Boston-area biotech companies through its 2010 Biotech Investment Awards program: Constellation Pharmaceuticals, Inc., Epizyme, Inc. and Karyopharm Therapeutics, Inc. Since the inception of this MMRF program in 2006, $11 million has been committed to 11 biotech companies in multi-year, results-driven funding for the development of innovative treatments for patients with multiple myeloma.

7 Jan 2011

Low incentive fails to 'switch off' brain regions involved in mind-wandering among ADHD children

Brain scans of children with attention-deficit/hyperactivity disorder (ADHD) have shown for the first time why people affected by the condition sometimes have difficulty in concentrating. The study, by experts at The University of Nottingham, may explain why parents often say that their child can maintain concentration when they are doing something that interests them, but struggles with boring tasks.

7 Jan 2011

Research roundup: Accountable Care Organizations; Electronic health records; Medicaid and deficit reductions

Health Affairs: Accountable Care Organizations: Making Them Work - The January issue of the journal features several articles examining initiatives underway that could help form ACOs, such as Blue Cross Blue Shield of Massachusetts' "Alternative Quality Contract,"a modified global payment model in which annual payments to medical groups are linked to a per member per month budget.

7 Jan 2011

Amorfix's AD diagnostic assay detects aggregated beta amyloid in spinal fluid

Amorfix Life Sciences, a product development company focused on diagnostics and therapeutics for misfolded protein diseases, today announced preliminary results indicating that their human Alzheimer's disease (AD) diagnostic assay can detect a signal from aggregated beta amyloid in the spinal fluid (CSF) from AD patients.

7 Jan 2011

Roundup: Calif. and health reform; Conn. mental health parity; Insurance premium increases in Iowa, Fla.

Wellmark Blue Cross and Blue Shield's proposed 11 percent health insurance premium increase is excessive, two experts have concluded. The company, which insures three-quarters of Iowans who buy their own policies, already raised premiums on those plans an average of 18 percent last spring. Wellmark sparked outcries when it announced in November that it wants to raise those rates again in order to keep up with rising prices and increased use of medical care (Leys, 1/7).

7 Jan 2011

GOP governors seek leeway to cut Medicaid rolls, The Wall Street Journal reports

Republican governors are pressing the Obama administration to make it easier for states to cut Medicaid enrollment, setting up a fight over one of states' costliest programs (Adamy, 1/7).

7 Jan 2011

Sucampo, Takeda initiate dosing in third lubiprostone phase 3 trial for opioid-induced bowel dysfunction

Sucampo Pharmaceuticals, Inc. and Takeda Pharmaceuticals North America, Inc. today announced the dosing of the first patient in the third phase 3 clinical trial of lubiprostone for the treatment of opioid-induced bowel dysfunction (OBD) in subjects with chronic, non-cancer pain, excluding those taking methadone. The primary endpoint is an overall responder rate based on the change from baseline in the reported frequency of spontaneous bowel movements (SBMs).

7 Jan 2011

New poll finds Americans split on repeal; Divide on Capitol Hill deepens

A new Gallup Poll found that public opinion is "closely divided" over whether Congress should vote to undo the health law. And on Capitol Hill, the divide is deep and entrenched, closely tracking with political loyalties. Even as GOP leaders point to the push to stop the health law as a way to "send a signal" to the American people, Senate Dems are plotting actions of their own.

7 Jan 2011

Research News and Research

Autism-vaccine link study – Complete fraud

Malaria drug makes cancer drug more effective

Infinity provides guidance on anticipated pipeline and business goals for 2011

MedImmune announces in-licensing agreement with Amgen for IL-1 pathway targeting novel monoclonal antibody

Scientists identify type of cell at the origin of brain tumors

Iroko reports positive results from Phase I clinical study of nanotechnology based unique formulation of naproxen

Majority of U.S. adults strongly support innovative programs to discourage teen pregnancy

Unexpected discovery holds promise for PTSD, other anxiety disorders

Sutro, Pfizer enter multi-year collaboration for novel peptide-based therapeutics

Radiosurgery may bring improvement for patients with extremely severe -compulsive disorder

Aratana closes $20 million Series A financing

Critical Diagnostics' high sensitivity Presage ST2 Assay receives CE Mark approval

MMRF awards $3 million under 2010 Biotech Investment Awards program

Low incentive fails to 'switch off' brain regions involved in mind-wandering among ADHD children

Research roundup: Accountable Care Organizations; Electronic health records; Medicaid and deficit reductions

Amorfix's AD diagnostic assay detects aggregated beta amyloid in spinal fluid

Roundup: Calif. and health reform; Conn. mental health parity; Insurance premium increases in Iowa, Fla.

GOP governors seek leeway to cut Medicaid rolls, The Wall Street Journal reports

Sucampo, Takeda initiate dosing in third lubiprostone phase 3 trial for opioid-induced bowel dysfunction

New poll finds Americans split on repeal; Divide on Capitol Hill deepens

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest Life Science News